Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Income (2016 - 2026)

Tonix Pharmaceuticals Holding has reported Operating Income over the past 4 years, most recently at -$41.5 million for Q1 2026.

  • For Q1 2026, Operating Income fell 158.73% year-over-year to -$41.5 million; the TTM value through Mar 2026 reached -$151.2 million, down 15.05%, while the annual FY2025 figure was -$125.7 million, 8.05% up from the prior year.
  • Operating Income for Q1 2026 was -$41.5 million at Tonix Pharmaceuticals Holding, up from -$48.3 million in the prior quarter.
  • Over five years, Operating Income peaked at -$15.6 million in Q3 2024 and troughed at -$77.3 million in Q2 2024.
  • A 4-year average of -$32.5 million and a median of -$28.3 million in 2025 define the central range for Operating Income.
  • Biggest five-year swings in Operating Income: tumbled 166.59% in 2024 and later surged 63.4% in 2025.
  • Year by year, Operating Income stood at -$27.3 million in 2023, then grew by 17.74% to -$22.5 million in 2024, then crashed by 114.8% to -$48.3 million in 2025, then grew by 13.98% to -$41.5 million in 2026.
  • Business Quant data shows Operating Income for TNXP at -$41.5 million in Q1 2026, -$48.3 million in Q4 2025, and -$33.1 million in Q3 2025.